Kiora Pharmaceuticals, Inc. develops and commercializes therapies for the treatment of ophthalmic diseases in the United States.Its lead product is KIO-301, a potential vision-restoring small molecule that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.
